Nov 12, 2019
Biomica Reports Positive Preliminary Results in Animal Studies in its Immuno-Oncology Program
Demonstrating Improved Anti-Tumor Activity Following Treatment with BMC 121 & BMC 127
Demonstrating Improved Anti-Tumor Activity Following Treatment with BMC 121 & BMC 127
The company has in-licensed IP and knowhow generated by Prof. Ada E. Yonath, Nobel Prize winner, who will advise Biomica on the program
This is the second program to enter pre-clinical studies; In addition, Prof. David T. Rubin, joins Biomica as a scientific & medical advisor
Aims to augment current cancer therapies by altering patients’ gut microbiome to improve response
